An hypothetical external validation of the ARRIVE trial in a European academic hospital.
Beatrice M G TassisMarta RuggieroAlice RonchiIlaria G RamezzanaGiulia BischettiEnrico IurlaroFrancesco D'AmbrosiFabrizio CiralliFabio A MoscaEnrico Mario FerrazziPublished in: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2020)
In our cohort, expectant management in low-risk pregnancies with late preterm screening of feto-maternal well-being seemed to achieve better maternal and perinatal outcomes than a universal policy of induction at 39 weeks. The results of the ARRIVE trial should be carefully evaluated in different demographic and clinical settings and cannot be extended to the general population.